Enoxaparin
Enoxaparin is a low molecular weight heparin (a blood thinner given by injection) used to prevent and treat dangerous blood clots, including deep vein thrombosis, and to treat certain heart conditions such as unstable angina and heart attack.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 29 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Enoxaparin (Lovenox) is an injectable blood thinner that mainly blocks clotting factor Xa, used to prevent and treat deep vein clots (DVT) that can travel to the lungs and to treat unstable angina (a warning-sign chest pain) and certain heart attacks. A familiar after-surgery and hospital standby since about 1993, it is available generically. Most people tolerate it well, noticing mainly injection site soreness and bruising, though bleeding is the main risk. The boxed warning is bleeding around the spine during an epidural or spinal procedure, which can cause permanent paralysis, so get urgent help for new leg numbness or weakness.
Clinical pearls
- Tell every doctor and dentist you use enoxaparin, especially before an epidural, spinal tap or any other procedure.
- Avoid NSAIDs such as ibuprofen, naproxen and ketorolac, plus aspirin, unless your prescriber approves, since they add to bleeding risk.
- Expect platelet blood tests, because a falling count or new clots can signal heparin-induced thrombocytopenia (HIT), an immune reaction.
- Severe kidney problems can let enoxaparin build up, so make sure your prescriber knows your kidney function.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Enoxaparin can cause bleeding around the spinal cord (spinal or epidural hematoma), which may lead to long-term or permanent paralysis. This risk applies to people who are on a blood thinner like this and are having epidural or spinal anesthesia or a spinal puncture.
The risk is higher with:
- An epidural catheter left in place
- Other drugs that affect clotting, such as NSAIDs, platelet inhibitors and other blood thinners
- A history of difficult or repeated epidural or spinal punctures
- A history of spinal deformity or spinal surgery
The best timing between enoxaparin and a spinal procedure is not known. Watch for new numbness or weakness, especially in the legs, and get urgent help if you notice it.
Patient information guide A plain-language walkthrough of Enoxaparin, written from its FDA label.
What Enoxaparin is used for
▾
Enoxaparin is a low molecular weight heparin with these supported uses:
- Preventing DVT after abdominal surgery, hip replacement or knee replacement
- Preventing DVT in medical patients with severely restricted mobility during acute illness
- Inpatient treatment of acute DVT, with or without pulmonary embolism, given with warfarin
- Outpatient treatment of acute DVT without pulmonary embolism, given with warfarin
- Preventing ischemic complications of unstable angina and non-Q-wave myocardial infarction
- Treating acute STEMI, managed medically or with PCI
These uses appear across the Lovenox, Enoxaparin Sodium and Enoxiluv Kit labels.
How Enoxaparin works
▾
Enoxaparin is a low molecular weight heparin with antithrombotic properties, meaning it helps stop clots from forming. It has a much higher ratio of anti-Factor Xa to anti-Factor IIa activity than regular heparin. Both are steps in the body’s clotting process.
Enoxaparin dosage
▾
Enoxaparin is injected, most often under the skin. Some labels also describe intravenous use, such as an initial dose for STEMI. Frequency can be once or twice daily depending on the condition, and surgery prevention usually lasts about 7 to 10 days.
- Your prescriber sets the exact dose and timing, so follow your label and their instructions.
- You should be checked for a bleeding disorder before starting, unless treatment is urgent.
Dosing details from the FDA-approved label
From the Enoxaparin prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Abdominal Surgery
- 40 mg by subcutaneous injection once a day (with the initial dose given 2 hours prior to surgery)
- Usual duration of administration is 7 to 10 days
- Hip or Knee Replacement Surgery
- 30 mg every 12 hours administered by subcutaneous injection
- Administer the initial dose 12 to 24 hours after surgery, provided that hemostasis has been established
- Usual duration 7 to 10 days
- A dose of 40 mg once a day subcutaneously may be considered for hip replacement surgery for up to 3 weeks, with the initial dose 12 (±3) hours prior to surgery
- Medical Patients during Acute Illness
- 40 mg once a day administered by subcutaneous injection
- Usual duration of administration is 6 to 11 days
- Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism - outpatient acute DVT without pulmonary embolism
- 1 mg/kg every 12 hours administered subcutaneously
- Initiate warfarin sodium therapy when appropriate (usually within 72 hours)
- Continue for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (INR 2 to 3)
- Average duration 7 days
- Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism - inpatient (hospital) treatment of acute DVT with pulmonary embolism or acute DVT without pulmonary embolism not candidates for outpatient treatment
- 1 mg/kg every 12 hours administered subcutaneously or 1.5 mg/kg once a day administered subcutaneously at the same time every day
- Initiate warfarin sodium therapy when appropriate (usually within 72 hours)
- Continue for a minimum of 5 days and until INR 2 to 3
- Average duration 7 days
- Unstable Angina and Non-Q-Wave Myocardial Infarction
- 1 mg/kg administered subcutaneously every 12 hours in conjunction with oral aspirin therapy (100 to 325 mg once daily)
- Treat for a minimum of 2 days and continue until clinical stabilization
- Usual duration 2 to 8 days
- Treatment of Acute ST-Segment Elevation Myocardial Infarction
- A single intravenous bolus of 30 mg plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg administered subcutaneously every 12 hours
- With aspirin 75 to 325 mg once daily
- Usual duration 8 days or until hospital discharge
- For PCI: if last subcutaneous dose was given more than 8 hours before balloon inflation, administer an intravenous bolus of 0.3 mg/kg
- If
- Maximum: 100 mg for the first two doses only, followed by 1 mg/kg dosing for the remaining doses
- Reduce the dosage in patients ≥75 years of age
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION See full prescribing information for dosing and administration information. ( 2 ) 2.1 Pretreatment Evaluation Evaluate all patients for a bleeding disorder before starting Enoxaparin Sodium Injection treatment, unless treatment is urgently needed. 2.2 Adult Dosage Abdominal Surgery The recommended dose of Enoxaparin Sodium Injection is 40 mg by subcutaneous injection once a day (with the initial dose given 2 hours prior to surgery) in patients undergoing abdominal surgery who are at risk for thromboembolic complications. The usual duration of administration is 7 to 10 days [ see Clinical Studies ( 14.1 ) ]. Hip or Knee Replacement Surgery The recommended dose of Enoxaparin Sodium Injection is 30 mg every 12 hours administered by subcutaneous injection in patients undergoing hip or knee replacement surgery. Administer the initial dose 12 to 24 hours after surgery, provided that hemostasis has been established. The usual duration of administration is 7 to 10 days [ see Clinical Studies ( 14.2 ) ]. A dose of Enoxaparin Sodium Injection of 40 mg once a day subcutaneously may be considered for hip replacement surgery for up to 3 weeks. Administer the initial dose 12 (±3) hours prior to surgery. Medical Patients During Acute Illness The recommended dose of Enoxaparin Sodium Injection is 40 mg once a day administered by subcutaneous injection for medical patients at risk for thromboembolic complications due to severely restricted mobility during acute illness. The usual duration of administration is 6 to 11 days [ see Clinical Studies ( 14.3 ) ]. Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism The recommended dose of Enoxaparin Sodium Injection is 1 mg/kg every 12 hours administered subcutaneously in patients with acute deep vein thrombosis without pulmonary embolism, who can be treated at home in an outpatient setting. The recommended dose of Enoxaparin Sodium Injection is 1 mg/kg every 12 hours administered subcutaneously or 1.5 mg/kg once a day administered subcutaneously at the same time every day for inpatient (hospital) treatment of patients with acute deep vein thrombosis with pulmonary embolism or patients with acute deep vein thrombosis without pulmonary embolism (who are not candidates for outpatient treatment).
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Enoxaparin side effects
▾
The most common side effects reported are:
Common side effects
- Bleeding
- Anemia (low red blood cells)
- Low platelet count (thrombocytopenia)
- Raised liver enzymes on blood tests
- Nausea
- Diarrhea
- Bruising (ecchymosis)
- Injection site pain
- Fever
- Swelling, including peripheral edema
- Confusion
When to get medical help
- Call your doctor or get emergency help for signs of serious bleeding.
- Get urgent help for new numbness, weakness or trouble moving your legs, or bladder or bowel changes, especially after an epidural or spinal procedure. These can be signs of a spinal hematoma.
- Report an allergic reaction such as itching, hives or swelling or trouble breathing.
- Tell your doctor about a drop in platelets or new clotting, which can happen with heparin-induced thrombocytopenia (HIT).
Enoxaparin warnings and precautions
▾
- Spinal or epidural hematoma can cause permanent paralysis if you have a spinal procedure or epidural while on enoxaparin.
- Bleeding risk is increased overall, so watch for signs of bleeding.
- Heparin-induced thrombocytopenia and low platelets can occur, so platelet counts are monitored.
- Do not swap enoxaparin with heparin or other low molecular weight heparins.
- Pregnant women with mechanical prosthetic heart valves may have a higher clot risk and need closer monitoring.
Enoxaparin interactions
▾
Drugs that raise bleeding risk should be stopped before starting enoxaparin when possible. If they are needed, expect close monitoring.
- Other anticoagulants add to bleeding risk.
- Aspirin, salicylates and other platelet inhibitors affect clotting.
- NSAIDs, including ketorolac, raise bleeding risk.
- Dipyridamole and sulfinpyrazone may also increase bleeding risk.
Interactions listed in the FDA-approved label
From the Enoxaparin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Anticoagulants: Agents which may enhance the risk of hemorrhage. Whenever possible discontinue prior to initiation of Enoxaparin Sodium Injection; if co-administration is essential, conduct close clinical and laboratory monitoring.
- Platelet inhibitors including acetylsalicylic acid: Agents which may enhance the risk of hemorrhage. Whenever possible discontinue prior to initiation of Enoxaparin Sodium Injection; if co-administration is essential, conduct close clinical and laboratory monitoring.
- Salicylates: Agents which may enhance the risk of hemorrhage. Whenever possible discontinue prior to initiation of Enoxaparin Sodium Injection; if co-administration is essential, conduct close clinical and laboratory monitoring.
- NSAIDs (including ketorolac tromethamine): Agents which may enhance the risk of hemorrhage. Whenever possible discontinue prior to initiation of Enoxaparin Sodium Injection; if co-administration is essential, conduct close clinical and laboratory monitoring.
- Dipyridamole: Agent which may enhance the risk of hemorrhage. Whenever possible discontinue prior to initiation of Enoxaparin Sodium Injection; if co-administration is essential, conduct close clinical and laboratory monitoring.
- Sulfinpyrazone: Agent which may enhance the risk of hemorrhage. Whenever possible discontinue prior to initiation of Enoxaparin Sodium Injection; if co-administration is essential, conduct close clinical and laboratory monitoring.
Read the label’s full interactions text
7 DRUG INTERACTIONS Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Enoxaparin Sodium Injection therapy. These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. If co-administration is essential, conduct close clinical and laboratory monitoring [ see Warnings and Precautions ( 5.1 ) ]. Discontinue agents which may enhance hemorrhage risk prior to initiation of Enoxaparin Sodium Injection or conduct close clinical and laboratory monitoring. ( 2.6 , 7 )
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Enoxaparin
▾
- Do not use with active major bleeding.
- Do not use with HIT in the past 100 days or circulating HIT antibodies.
- Do not use with a known allergy to enoxaparin, heparin or pork products.
- Multiple-dose vials contain benzyl alcohol, so avoid them if you are allergic to it.
- Tell your doctor about any bleeding disorder or planned spinal or epidural procedure.
- Severe kidney impairment may require a dose adjustment.
- Tell your doctor if you are pregnant with a mechanical heart valve.
Enoxaparin overdose
▾
An accidental overdose can cause bleeding complications. Protamine sulfate given slowly by vein can largely neutralize enoxaparin, though it never completely reverses the effect. Protamine itself can cause severe low blood pressure and allergic-type reactions, so it is given only where emergency care is available.
What Enoxaparin does in the body
▾
Enoxaparin has a much higher anti-Factor Xa to anti-Factor IIa ratio than heparin. It can raise clotting tests such as thrombin time and aPTT, by up to about 1.8 times control values. The effect on aPTT was about 16% higher on Day 1 than on Day 4.
How your body processes Enoxaparin
▾
After an injection under the skin, enoxaparin’s clot-blocking activity peaks in about 3 to 5 hours. It is absorbed almost completely, with bioavailability of about 100%. The liver breaks it down into much weaker fragments, and the kidneys clear some of it. Its half-life is about 4.5 hours after a single dose to about 7 hours after repeated doses.
How to store Enoxaparin
▾
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). Store in the original carton or packaging until ready to use. Keep out of the reach of children.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Enoxaparin: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Enoxaparin — the kind of thing our pharmacy team would talk through with you at the counter.
What is enoxaparin for?
▾
How will I take it?
▾
What side effects should I expect?
▾
Is there anything serious I should watch for?
▾
Can I take pain relievers with it?
▾
Who shouldn’t use it?
▾
Is Enoxaparin available over the counter?
▾
When was Enoxaparin first available?
▾
Who makes Enoxaparin?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Enoxaparin on HelloPharmacist
Enoxaparin forms and strengths (how it comes)
Enoxaparin is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Lovenox is used to prevent DVT after abdominal, hip or knee surgery and in medical patients with severely restricted mobility.
- Lovenox is used to treat acute DVT alongside warfarin.
- Lovenox is used for unstable angina, non-Q-wave heart attack and STEMI.
- Enoxiluv Kit and Enoxaparin Sodium list the same uses.
- Lovenox is given by subcutaneous injection for most uses, and some Lovenox labels also list intravenous use.
- Enoxaparin Sodium labels list subcutaneous use, and some also list intravenous use.
- Enoxiluv Kit is listed with subcutaneous administration.
- Lovenox and the other products require a bleeding disorder check before starting, unless treatment is urgent.
Show 2 more strengths Show fewer strengths
Enoxaparin on the U.S. market: products, makers and brands
How Enoxaparin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
16 companies list 144 Enoxaparin product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1993. Brand names on the directory include Lovenox; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (8) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Enoxaparin is used (Medicaid data)
A general measure of how commonly Enoxaparin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Enoxaparin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Enoxaparin prescribed? Of the 1,601 medications we measure, Enoxaparin ranks #343 by Medicaid prescriptions — more than 79% of them.
Utilization by Enoxaparin product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe Most dispensed
Summed across the 19 of 53 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854235
1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe
Summed across the 14 of 48 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854248
0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe
Summed across the 12 of 49 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854241
0.6 ML enoxaparin sodium 100 MG/ML Prefilled Syringe
Summed across the 14 of 48 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854238
0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe
Summed across the 15 of 48 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854228
0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe
Summed across the 13 of 46 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854245
enoxaparin sodium 100 MG/ML Injectable Solution
Summed across the 7 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854255
1 ML enoxaparin sodium 150 MG/ML Prefilled Syringe
Summed across the 9 of 46 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 854252
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Enoxaparin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 103 of 351 listed Enoxaparin NDCs with Medicaid activity.
Compare Enoxaparin products
A representative set of FDA-listed product records for Enoxaparin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 100 mg/mL | Subcutaneous | Amphastar Pharmaceuticals, Inc. × 5 listings | ANDA | View NDC → |
| 150 mg/mL | Subcutaneous | Amphastar Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 300 mg/3 mL | Intravenous, Subcutaneous | Amphastar Pharmaceuticals, Inc. | ANDA | View NDC → |
| 30 mg/0.3 mL | Subcutaneous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 40 mg/0.4 mL | Subcutaneous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 60 mg/0.6 mL | Subcutaneous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 80 mg/0.8 mL | Subcutaneous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 100 mg/mL | Subcutaneous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 120 mg/0.8 mL | Subcutaneous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 150 mg/mL | Subcutaneous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 100 mg/mL | Subcutaneous | BluePoint Laboratories × 10 listings | ANDA | View NDC → |
| 150 mg/mL | Subcutaneous | BluePoint Laboratories × 4 listings | ANDA | View NDC → |
| 300 mg/3 mL | Intravenous, Subcutaneous | BluePoint Laboratories × 2 listings | ANDA | View NDC → |
| 40 mg/0.4 mL | Subcutaneous | Cardinal Health 107, LLC | NDA | View NDC → |
| 40 mg/0.4 mL | Subcutaneous | Cardinal Health 107, LLC | ANDA | View NDC → |
| 100 mg/mL | Subcutaneous | Cardinal Health 107, LLC × 5 listings | ANDA | View NDC → |
| 100 mg/mL | Subcutaneous | Civica, Inc. | ANDA | View NDC → |
| 30 mg/0.3 mL | Subcutaneous | Fresenius Kabi USA, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 30 mg/0.3 mL | Subcutaneous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 40 mg/0.4 mL | Subcutaneous | Fresenius Kabi USA, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 40 mg/0.4 mL | Subcutaneous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 60 mg/0.6 mL | Subcutaneous | Fresenius Kabi USA, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 60 mg/0.6 mL | Subcutaneous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 80 mg/0.8 mL | Subcutaneous | Fresenius Kabi USA, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 80 mg/0.8 mL | Subcutaneous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 100 mg/mL | Subcutaneous | Fresenius Kabi USA, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 100 mg/mL | Subcutaneous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 120 mg/0.8 mL | Subcutaneous | Fresenius Kabi USA, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 120 mg/0.8 mL | Subcutaneous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 150 mg/mL | Subcutaneous | Fresenius Kabi USA, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 150 mg/mL | Subcutaneous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 300 mg/3 mL | Intravenous, Subcutaneous | Fresenius Kabi USA, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 30 mg/0.3 mL | Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 40 mg/0.4 mL | Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 60 mg/0.6 mL | Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 80 mg/0.8 mL | Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 100 mg/mL | Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 120 mg/0.8 mL | Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 150 mg/mL | Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 30 mg/0.3 mL | Subcutaneous | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 40 mg/0.4 mL | Subcutaneous | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 60 mg/0.6 mL | Subcutaneous | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 80 mg/0.8 mL | Subcutaneous | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 100 mg/mL | Subcutaneous | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 120 mg/0.8 mL | Subcutaneous | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 150 mg/mL | Subcutaneous | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 100 mg/mL | Subcutaneous | Meitheal Pharmaceuticals Inc. × 5 listings | ANDA | View NDC → |
| 150 mg/mL | Subcutaneous | Meitheal Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 300 mg/3 mL | Intravenous, Subcutaneous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
Showing 76 of 144 products — FDA National Drug Code Directory. See every product, package size and price: browse all 144 Enoxaparin NDCs →
Enoxaparin side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Enoxaparin — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Enoxaparin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Enoxaparin FDA approval history
How Enoxaparin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Enoxaparin recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 2 Enoxaparin recalls since July 2021. One of them is still ongoing and is listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Enoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled syringes further packaged in bags of 5 prefilled syringes, Rx Only, Dist. by: Sandoz Inc., Princeton, NJ 08540, Outer pack… Lots: Outer package - NDC 55154-3543-5, Lot SAD08033AA Inner label - NDC 0781-3238-01, Lot SAF13211A FDA record D-0597-2025 →
- Enoxaparin Sodium Injection, USP, 150MG/ML Single-Dose Syringes with Automatic Safety Device, For Subcutaneous Injection, Ten 1 mL Syringes per box, Rx Only, Sandoz Inc, Princeton, NJ 08540. NDC: 078… Lots: Batch SAH06821A FDA record D-0179-2024 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 67108 2 dose forms · 8 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 372012In current FDA listingsClinical drug / strength (SCD) sodium 100 MG/MLRxCUI 854255 -
Dose form (SCDF) Prefilled Syringe RxCUI 727722No current FDA listingClinical drug / strength (SCD) 0.3 ML enoxaparin sodium 100 MG/MLRxCUI 8542280.4 ML enoxaparin sodium 100 MG/MLRxCUI 8542350.6 ML enoxaparin sodium 100 MG/MLRxCUI 8542380.8 ML enoxaparin sodium 100 MG/MLRxCUI 8542410.8 ML enoxaparin sodium 150 MG/MLRxCUI 8542451 ML enoxaparin sodium 100 MG/MLRxCUI 8542481 ML enoxaparin sodium 150 MG/MLRxCUI 854252
Look up RxCUI 67108 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Enoxaparin supply and shortage status
Whether Enoxaparin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Enoxaparin costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Injection · Subcutaneous | 40 mg/0.4 mL | $6.78 per mL | NDC details & price history |
| Injection · Subcutaneous | 300 mg/3 mL | $9.87 per mL | NDC details & price history |
| Injection, Solution · Subcutaneous | 150 mg/mL | $14.74 per mL | NDC details & price history |
| Injection, Solution · Subcutaneous | 120 mg/0.8 mL | $17.38 per mL | NDC details & price history |
| Injection, Solution · Subcutaneous | 100 mg/mL | $9.67 per mL | NDC details & price history |
| Injection, Solution · Subcutaneous | 80 mg/0.8 mL | $10.02 per mL | NDC details & price history |
| Injection, Solution · Subcutaneous | 60 mg/0.6 mL | $11.53 per mL | NDC details & price history |
| Injection, Solution · Subcutaneous | 40 mg/0.4 mL | $10.68 per mL | NDC details & price history |
| Injection, Solution · Subcutaneous | 30 mg/0.3 mL | $13.12 per mL | NDC details & price history |
| Injection, Solution · Intravenous; Subcutaneous | 150 mg/mL | $8.90 per mL | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Enoxaparin brand names
Enoxaparin is sold under one brand name in the FDA directory — Lovenox. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Enoxaparin: manufacturers and labelers
16 companies list Enoxaparin products with the FDA. By number of product records, the largest are Sanofi-Aventis U.S. LLC, BluePoint Laboratories, Fresenius Kabi USA, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Enoxaparin drug class (RxNorm)
Enoxaparin belongs to the Low Molecular Weight Heparin class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Enoxaparin page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Cardinal Health is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →